Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Perdiguero, Beatriz ^a   Gómez, Carmen Elena ^a   Nájera, Jose Luis ^a   Sorzano, Carlos Oscar S ^a   Delaloye, Julie ^b   González Sanz, Rubén ^a   Jiménez, Victoria ^a   Roger, Thierry ^b   Calandra, Thierry ^b   Pantaleo, Giuseppe ^b   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCL 2 LIKE PROTEIN F1; CYTOKINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON; NEF PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEPTIDES AND PROTEINS; POL PROTEIN; POXVIRUS VECTOR; RECOMBINANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 C MODIFIED VACCINIA ANKARA VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DELETION MUTANT; DENDRITIC CELL; F1L GENE; FEMALE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; VACCINATION; VIRUS GENE; VIRUS REPLICATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CHICK EMBRYO; CYTOKINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GENE DELETION; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON TYPE I; MACROPHAGES; MICE; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES; VACCINIA VIRUS; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 84868305785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048524     Document Type: Article

References (89)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. Climent N, Guerra S, Garcia F, Rovira C, Miralles L, et al. (2011) Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One 6: e19644.
3. Garcia-Arriaza J, Najera JL, Gomez CE, Tewabe N, Sorzano CO, et al. (2011) A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6: e24244.
4. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, et al. (2008) Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 82: 2975-2988.
5. Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, et al. (2008) Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198: 1482-1490.
6. Aboud S, Nilsson C, Karlen K, Marovich M, Wahren B, et al. (2010) Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin Vaccine Immunol 17: 1124-1131.
7. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, et al. (2010) Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5: e13983.
8. Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, et al. (2010) Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One 5: e8816.
9. Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, et al. (2009) A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 25: 1107-1116.
10. Garcia F, Bernaldo de Quiros JC, Gomez CE, Perdiguero B, Najera JL, et al. (2011) Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 29: 8309-8316.
11. Gomez CE, Najera JL, Perdiguero B, Garcia-Arriaza J, Sorzano CO, et al. (2011) The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol 85: 11468-11478.
12. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, et al. (2011) Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 203: 610-619.
13. Antoine G, Scheiflinger F, Dorner F, Falkner FG, (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
14. Meyer H, Sutter G, Mayr A, (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 (Pt 5): 1031-1038.
15. Carroll MW, Moss B, (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
16. Sutter G, Moss B, (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89: 10847-10851.
17. Sutter G, Staib C, (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3: 263-271.
18. Didierlaurent A, Ramirez JC, Gherardi M, Zimmerli SC, Graf M, et al. (2004) Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine 22: 3395-3403.
19. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, et al. (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
20. Shisler JL, Moss B, (2001) Immunology 102 at poxvirus U: avoiding apoptosis. Semin Immunol 13: 67-72.
21. Taylor JM, Barry M, (2006) Near death experiences: poxvirus regulation of apoptotic death. Virology 344: 139-150.
22. Roulston A, Marcellus RC, Branton PE, (1999) Viruses and apoptosis. Annu Rev Microbiol 53: 577-628.
23. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G, (2008) Viral control of mitochondrial apoptosis. PLoS Pathog 4: e1000018.
24. Adams JM, (2003) Ways of dying: multiple pathways to apoptosis. Genes Dev 17: 2481-2495.
25. Hengartner MO, (2000) The biochemistry of apoptosis. Nature 407: 770-776.
26. Riedl SJ, Shi Y, (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907.
27. Albert ML, Sauter B, Bhardwaj N, (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86-89.
28. Wasilenko ST, Stewart TL, Meyers AF, Barry M, (2003) Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc Natl Acad Sci U S A 100: 14345-14350.
29. Stewart TL, Wasilenko ST, Barry M, (2005) Vaccinia virus F1L protein is a tail-anchored protein that functions at the mitochondria to inhibit apoptosis. J Virol 79: 1084-1098.
30. Wasilenko ST, Banadyga L, Bond D, Barry M, (2005) The Vaccinia Virus F1L Protein Interacts with the Proapoptotic Protein Bak and Inhibits Bak Activation. J Virol 79: 14031-14043.
31. Youle RJ, Strasser A, (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
32. Postigo A, Cross JR, Downward J, Way M, (2006) Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis. Cell Death Differ 13: 1651-1662.
33. Campbell S, Hazes B, Kvansakul M, Colman P, Barry M, (2010) Vaccinia virus F1L interacts with Bak using highly divergent Bcl-2 homology domains and replaces the function of Mcl-1. J Biol Chem 285: 4695-4708.
34. Kvansakul M, Yang H, Fairlie WD, Czabotar PE, Fischer SF, et al. (2008) Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 15: 1564-1571.
35. Taylor JM, Quilty D, Banadyga L, Barry M, (2006) The Vaccinia Virus Protein F1L Interacts with Bim and Inhibits Activation of the Pro-apoptotic Protein Bax. J Biol Chem 281: 39728-39739.
36. Fischer SF, Ludwig H, Holzapfel J, Kvansakul M, Chen L, et al. (2006) Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. Cell Death Differ 13: 109-118.
37. Postigo A, Way M, (2012) The vaccinia virus-encoded Bcl-2 homologues do not act as direct Bax inhibitors. J Virol 86: 203-213.
38. Zhai D, Yu E, Jin C, Welsh K, Shiau CW, et al. (2010) Vaccinia virus protein F1L is a caspase-9 inhibitor. J Biol Chem 285: 5569-5580.
39. Yu E, Zhai D, Jin C, Gerlic M, Reed JC, et al. (2011) Structural determinants of caspase-9 inhibition by the vaccinia virus protein, F1L. J Biol Chem 286: 30748-30758.
40. Eitz Ferrer P, Potthoff S, Kirschnek S, Gasteiger G, Kastenmuller W, et al. (2011) Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-beta-dependent induction of pro-apoptotic Noxa. PLoS Pathog 7: e1002083.
41. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, et al. (2006) The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 146: 344-353.
42. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M, (2011) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11: 189-217.
43. Pantaleo G, Esteban M, Jacobs B, Tartaglia J, (2010) Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS 5: 391-396.
44. Gomez CE, Najera JL, Jimenez V, Bieler K, Wild J, et al. (2007) Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine. 25: 1969-1992.
45. Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, et al. (2009) Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 83: 7176-7184.
46. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
47. Postigo A, Ferrer PE, (2009) Viral inhibitors reveal overlapping themes in regulation of cell death and innate immunity. Microbes Infect 11: 1071-1078.
48. Gomez CE, Najera JL, Jimenez EP, Jimenez V, Wagner R, et al. (2007) Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine. 25: 2863-2885.
49. Robinson HL, Sharma S, Zhao J, Kannanganat S, Lai L, et al. (2007) Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses 23: 1555-1562.
50. Wild J, Bieler K, Kostler J, Frachette MJ, Jeffs S, et al. (2009) Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol 22: 309-319.
51. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53.
52. Unsoeld H, Pircher H, (2005) Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. J Virol 79: 4510-4513.
53. McElrath MJ, Haynes BF, (2010) Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554.
54. Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL, (2006) Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87: 29-38.
55. Staib C, Kisling S, Erfle V, Sutter G, (2005) Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 86: 1997-2006.
56. Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, et al. (2008) Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA). PLoS ONE 3: e1638.
57. Garcia-Arriaza J, Najera JL, Gomez CE, Sorzano CO, Esteban M, (2010) Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5: e12395.
58. Falivene J, Del Medico Zajac MP, Pascutti MF, Rodriguez AM, Maeto C, et al. (2012) Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One 7: e32220.
59. Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, et al. (2011) Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 6: e16819.
60. Kibler KV, Gomez CE, Perdiguero B, Wong S, Huynh T, et al. (2011) Improved NYVAC-based vaccine vectors. PLoS One 6: e25674.
61. Gomez CE, Perdiguero B, Najera JL, Sorzano CO, Jimenez V, et al. (2012) Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86: 5026-5038.
62. Zhao XQ, Huang XL, Gupta P, Borowski L, Fan Z, et al. (2002) Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells. J Virol 76: 3007-3014.
63. Gomez CE, Perdiguero B, Jimenez V, Filali-Mouhim A, Ghneim K, et al. (2012) Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. PLoS One. 7: e35485.
64. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
65. Lanzavecchia A, Sallusto F, (2004) Lead and follow: the dance of the dendritic cell and T cell. Nat Immunol 5: 1201-1202.
66. Sigal LJ, Rock KL, (2000) Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and-independent pathways of antigen presentation. J Exp Med 192: 1143-1150.
67. Heath WR, Carbone FR, (2001) Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1: 126-134.
68. Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, et al. (2006) Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350: 276-288.
69. Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I, (2007) Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 81: 11925-11936.
70. Chahroudi A, Garber DA, Reeves P, Liu L, Kalman D, et al. (2006) Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J Virol 80: 8469-8481.
71. Motta I, Andre F, Lim A, Tartaglia J, Cox WI, et al. (2001) Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 167: 1795-1802.
72. Larsson M, Fonteneau JF, Somersan S, Sanders C, Bickham K, et al. (2001) Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 31: 3432-3442.
73. Ray A, Dittel BN (2010) Isolation of mouse peritoneal cavity cells. J Vis Exp 35: doi: 10.3791/1488.
74. Chahroudi A, Chavan R, Kozyr N, Waller EK, Silvestri G, et al. (2005) Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol 79: 10397-10407.
75. Sanchez-Puig JM, Sanchez L, Roy G, Blasco R, (2004) Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J 1: 10.
76. Liu L, Chavan R, Feinberg MB, (2008) Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol 9: 15.
77. Flechsig C, Suezer Y, Kapp M, Tan SM, Loffler J, et al. (2011) Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells. Cytotherapy 13: 739-752.
78. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, et al. (2005) The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341: 91-101.
79. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, et al. (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428: 182-185.
80. Gomez CE, Rodriguez D, Rodriguez JR, Abaitua F, Duarte C, Esteban M, (2002) Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified Vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with thw vaccinia virus Western Reserve (WR) vector. Vaccine 20: 961-971.
81. Ramirez JC, Gherardi MM, Esteban M, (2000) Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74: 923-933.
82. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5: e1000480.
83. Lehmann MH, Kastenmuller W, Kandemir JD, Brandt F, Suezer Y, et al. (2009) Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J Virol 83: 2540-2552.
84. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, et al. (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15: 293-299.
85. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
86. Zhang Z, Abrahams MR, Hunt LA, Suttles J, Marshall W, et al. (2005) The vaccinia virus N1L protein influences cytokine secretion in vitro after infection. Ann N Y Acad Sci 1056: 69-86.
87. DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, et al. (2004) Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 279: 36570-36578.
88. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, et al. (1995) Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181: 45-54.
89. Najera JL, Gomez CE, Garcia-Arriaza J, Sorzano CO, Esteban M, (2010) Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5: e11406.